{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T03:49:24Z","timestamp":1772941764889,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00,004\/06"],"award-info":[{"award-number":["MC_UU_00,004\/06"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.urolonc.2025.07.013","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T12:43:50Z","timestamp":1755780230000},"page":"661.e9-661.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy"],"prefix":"10.1016","volume":"43","author":[{"given":"C.N.","family":"Sternberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Squifflet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.D.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Burdett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Teitsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.Y.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Stoeckle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Torti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Cote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.M.","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zhegalik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.F.","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Collette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Burzykowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Buyse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.07.013_bib0001","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0002","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2005.04.005","article-title":"Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0003","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1464-410X.2010.09912.x","article-title":"Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience","volume":"108","author":"Yafi","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0004","article-title":"NCCN Practice Guidelines in oncology (NCCN Guidelines)","volume":"2","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","article-title":"Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials","volume":"81","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0006","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00345-018-2371-y","article-title":"Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era","volume":"36","author":"Fletcher","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0007","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0008","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl 4","key":"10.1016\/j.urolonc.2025.07.013_bib0009","article-title":"AMBASSADOR Alliance A031501: phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation","volume":"42","author":"Apolo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/oncolo\/oyac006","article-title":"Surrogacy beyond prognosis: the importance of \u201ctrial-level\u201d surrogacy","volume":"27","author":"Buyse","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0011","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0090-4295(84)80080-1","article-title":"Cisplatin as adjunctive treatment for invasive bladder carcinoma: tolerance and toxicities","volume":"23","author":"Einstein","year":"1984","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0012","first-page":"279","article-title":"Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer","volume":"8","author":"Skinner","year":"1990","journal-title":"Semin Urol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0013","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-5347(17)32822-7","article-title":"Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomised trial","volume":"152","author":"Studer","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005392-199501000-00019","article-title":"Adjuvant polychemotherapy of non-organ confined bladder cancer after radical cystectomy revisited: long term results of a controlled prospective study and further clinical experience","volume":"153","author":"St\u00f6ckle","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0022-5347(01)66430-9","article-title":"A randomised trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer","volume":"155","author":"Freiha","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0016","first-page":"5","article-title":"Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study","volume":"11","author":"Bono","year":"1997","journal-title":"Acta Urologica Italica"},{"issue":"suppl 18","key":"10.1016\/j.urolonc.2025.07.013_bib0017","doi-asserted-by":"crossref","first-page":"LBA4518","DOI":"10.1200\/jco.2010.28.18_suppl.lba4518","article-title":"Randomized phase III trial comparing adjuvant paclitaxel\/gemcitabine\/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99\/01 study","volume":"28","author":"Paz-Ares","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0018","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1200\/JCO.2010.34.4028","article-title":"Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status","volume":"29","author":"Stadler","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0019","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/annonc\/mdr354","article-title":"Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial","volume":"23","author":"Cognetti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0020","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S1569-9056(14)60780-6","article-title":"Radical cystectomy with our without shortened course of adjuvant chemotherapy in high risk, muscle-invasive bladder cancer: results of a single centre prospective randomized trial","volume":"13","author":"Zhegalik","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0021","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deffered chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.urolonc.2025.07.013_bib0022","first-page":"279","article-title":"Radical cystectomy \u00b1 adjuvant chemotherapy in bladder cancer (PT3\/PN1-2, M0): a randomised phase III study. Abstract 1147","volume":"165","author":"Otto","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0023","series-title":"The evaluation of surrogate endpoints","author":"Burzykowski","year":"2002"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0024","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","article-title":"Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pst.207","article-title":"Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation","volume":"5","author":"Burzykowski","year":"2006","journal-title":"Pharm Stat"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0026","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(18)30750-2","article-title":"Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis","volume":"20","author":"Saad","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0027","doi-asserted-by":"crossref","first-page":"8664","DOI":"10.1200\/JCO.2005.01.6071","article-title":"Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials","volume":"23","author":"Sargent","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0028","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jnci\/djt270","article-title":"Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis","volume":"105","author":"Oba","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0029","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx133","article-title":"Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy","volume":"110","author":"Suciu","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0030","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(00)02528-9","article-title":"Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer","volume":"356","author":"Buyse","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0031","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","article-title":"Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer","volume":"26","author":"Burzykowski","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0032","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/jnci\/djt269","article-title":"Progression-free survival as a surrogate for overall survival in advanced\/recurrent gastric cancer trials: a meta-analysis","volume":"105","author":"Paoletti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0033","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0034","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/annonc\/mdw132","article-title":"Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer","volume":"27","author":"Michiels","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.01.001","article-title":"Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: results from a machine learning-based analysis of a large multi-institutional database","volume":"42","author":"Porreca","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0036","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.22.02363","volume":"41","author":"Squifflet","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.07.013_bib0037","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:16:54Z","timestamp":1772882214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925002698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1078143925002698"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}